Back to top

pharmaceuticals: Archive

Shaun Pruitt

Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist

BETRNegative Net Change COGTPositive Net Change CELCNegative Net Change RGCPositive Net Change OPENPositive Net Change IWMPositive Net Change

Zacks Equity Research

Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III

RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.

RHHBYNegative Net Change LLYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change

Ahan Chakraborty

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.

NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change

Zacks Equity Research

WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?

Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.

NVOPositive Net Change LLYPositive Net Change WVENegative Net Change

Kinjel Shah

GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?

GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

AZNNegative Net Change GSKPositive Net Change NVOPositive Net Change LLYPositive Net Change

Sundeep Ganoria

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change

Mark Vickery

Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson

Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.

JNJPositive Net Change XOMNo Net Change TRMBPositive Net Change AVGONegative Net Change SYFPositive Net Change ITICPositive Net Change APTVPositive Net Change FRDPositive Net Change

Ahan Chakraborty

Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.

NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change

Kinjel Shah

PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change

Kinjel Shah

JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

JNJPositive Net Change PFEPositive Net Change

Aparajita Dutta

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

BMYNegative Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change

Kinjel Shah

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

SNYPositive Net Change BMYNegative Net Change NVOPositive Net Change TEVAPositive Net Change

Kinjel Shah

MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?

Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.

MRKPositive Net Change MRNAPositive Net Change CDTXPositive Net Change SMMTPositive Net Change

Zacks Equity Research

GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.

NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change

Sanghamitra Saha

Pharma ETF (XPH) Hits a New 52-Week High

Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?

XPHNegative Net Change

Zacks Equity Research

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.

RDYPositive Net Change TEVAPositive Net Change SDZNYPositive Net Change

Ekta Bagri

Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

BIIBNegative Net Change BMYNegative Net Change LLYPositive Net Change

Kinjel Shah

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.

JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change

Zacks Equity Research

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know

Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.

ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change PRAXPositive Net Change

Zacks Equity Research

Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status

INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

INCYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change

Zacks Equity Research

Company News for Dec 8, 2025

Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG

NRGPositive Net Change MRKPositive Net Change NFLXPositive Net Change WBDNegative Net Change VSCOPositive Net Change

Nalak Das

Watch 5 Bigwigs in December After Double-Digit Returns Past Month

Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.

MRKPositive Net Change FCXPositive Net Change WMTPositive Net Change AMATNegative Net Change CVNAPositive Net Change

Zacks Equity Research

ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study

Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.

ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change ABSINegative Net Change

Zacks Equity Research

CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know

Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.

ANIPPositive Net Change CRMDPositive Net Change CAPRNegative Net Change ARQTNegative Net Change

Ekta Bagri

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

BIIBNegative Net Change RPRXPositive Net Change DNLINegative Net Change TAKPositive Net Change